Empowering Consumers as Contributors for Health Product Safety: Lessons from the Philippines

Drug Safety

Volumn 38, Issue 4, 2015, Pages 329-335

  Hartigan Go, Kenneth ^a  

^a Asian Institute of Management   (Philippines)

Author keywords

[No Author keywords available]

Indexed keywords

COSMETIC;

CHEMISTRY; CONSUMER; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMAN; INFORMATION PROCESSING; PHILIPPINES; POSTMARKETING SURVEILLANCE; PROCEDURES; STATISTICS AND NUMERICAL DATA;

CONSUMER PARTICIPATION; COSMETICS; DATA COLLECTION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; PHILIPPINES; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 84939945747     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-015-0274-z     Document Type: Editorial

References (24)

1. Monitoring Medicines. EU-FP7 Monitoring Medicines project. Available at: http://www.monitoringmedicines.org. Accessed 9 Feb 2015.
2. Raine JM. Drug safety: reporting systems for the general public. BMJ. 2012;345:e4916.
3. Christensen CM, Grossman JH, Hwang J. Integrating to make it happen. In: Christensen CM, Grossman JH, Hwang J, editors. The innovator’s prescription: a disruptive solution for health care. New York: McGraw-Hill; 2009. p. 183–220.
4. Hartigan-Go K. Challenges of drug risk communications in the Philippines. Drug Saf. 2012;35(11):995–1004.
5. Van Hunsel F, Harmark L, Pal S, Olsson S, Van Grootheest K. Experiences with adverse drug reaction reporting by patients. Drug Saf. 2012;35(1):45–60.
6. Hsiao W, Reich MR, Takemi T. Regulations. In: Roberts MJ, Hsiao W, Berman P, Reich MR, editors. Getting health reform right: a guide to improving performance and equity. Oxford: Oxford University Press; 2003. p. 247–80.
7. Bennis W, Goleman D, Biederman PW. Creating a culture of candor. In: Bennis W, Goleman D, O’Toole J, editors. Transparency: how leaders create a culture of candor. San Francisco (CA): Jossey-Bass; 2008. p. 1–43.
8. Republic of the Philippines Food and Drug Administration. FDA Advisory No. 2014-058. Warning on fraudulent sales strategies employed by websites involved in buy and sell of health products. Available at: http://www.fda.gov.ph/advisories/312-others/177689-fda-advisory-no-2014-058. Accessed 9 Feb 2015.
9. Republic of the Philippines Food and Drug Administration. FDA Advisory No. 2014-041. Deceptive on-line sale and marketing of inner power stem cell booster. Available at: http://www.fda.gov.ph/advisories/pharmaceutical/161953-fda-advisory-no-2014-041. Accessed 9 Feb 2015.
10. Republic of the Philippines Food and Drug Administration. FDA Advisory No. 2014-042. Public warning against advertisement, promotion, offer for sale and use of “Bangkok Pills”. Available at: http://www.fda.gov.ph/advisories/pharmaceutical/161954-fda-advisory-no-2014-042. Accessed 9 Feb 2015.
11. Republic of the Philippines Food and Drug Administration. FDA Advisory No. 2014-051. Public warning against false advertisement, promotion, offer for sale and use of “Optrimax Plum”. Available at: http://www.fda.gov.ph/advisories/food/169794-fda-advisory-no-2014-051. Accessed 9 Feb 2015.
12. Hopkins DM, Kontnik LT, Turnage MT. Pharmaceuticals. In: Hopkins DM, Kontnik LT, Turnage MT, editors. Counterfeiting exposed. Hoboken (NJ): Wiley; 2003. p. 69–93.
13. McAdams T, Neslund N, Zucker KD. Business, torts and product liability. In: McAdams T, Neslund N, Zucker KD, editors. Law, business and society. 10th ed. New York: McGraw-Hill; 2012. p. 282–330.
14. Rifkin E, Bouwer E. The physician’s and patient’s perspectives. In: Rifkin E, Bouwer E, editors. The illusion of certainty (health benefits and risks). Berlin: Springer; 2007. p. 167–87.
15. Frank RG. Behavioral economics and health economics. In: Diamond P, Vartiainen H, editors. Behavioral economics and its applications. Princeton: Princeton University Press; 2007. p. 195–234.
16. Mowen JC, Minor M. Information processing I: involvement and perception. In: Mowen JC, Minor M, editors. Consumer behavior. 5th ed. USA: Prentice Hall; 2000. p. 64–6.
17. Van Hunsel F, ten Berge E, Borgsteede SD, et al. What motivates patients to report ADR? Ann Pharmacother. 2010;44:936–7.
18. East R, Wright M, Vanhuele M. Consumer behaviour: applications in marketing. Thousand Oaks (CA): Sage Publishing; 2008. p. 166–90.
19. Republic of Philippines Food and Drug Administration. FDA Advisory No. 2014-057. Patient counselling by physicians and pharmacists. Available at: http://www.fda.gov.ph/attachments/article/177652/FA2014-057%20-%20Patient%20Counselling%20by%20the%20Physician%20and%20Pharmacists.pdf. Accessed 9 Feb 2015.
20. Van Hunsel F, van der Welle C, Passier A, et al. Motives for reporting adverse drug reactions by patient-reporters in the Netherlands. Eur J Clin Pharmacol. 2010. Available at: http://www.lareb.nl/LarebCorporateWebsite/media/Publicaties/2010_3_EJCP_Motives_reporting_ADRs_patient-reporters_Netherlands.pdf. Accessed 20 Oct 2014.
21. Van Hunsel F, van Puijenbroek E, de Jong-van den Berg LTW, et al. Media attention and influence on reporting odds ratio in disproportionality analysis: an example of patient reporting of statins. Pharmacoepidemiol Drug Saf. 2010;19:26–32.
22. Kotler P, Roberto EL. The nature and role of social campaigns to change public behavior. In: Social marketing. New York: Free Press, Macmillan Inc.; 1989. p. 3–23.
23. De Savigny D, Adam T, editors. Systems thinking for health systems strengthening. World Health Organization; 2009. p. 32.
24. Goldfarb A, Ho TH, Amaldoss W, et al. Behavioral models of managerial decision-making. Mark Lett. 2012;23:405–21.